Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 3, 2015, Pages 294-303

  Bode, B ^a   Stenlof K ^b   Harris, S ^c   Sullivan, D ^d   Fung, A ^d   Usiskin, K ^d   Meininger, G ^d  

^a ATLANTA DIABETES ASSOCIATES   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; Phase III study; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

ANTIFUNGAL AGENT; CANAGLIFLOZIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; PLACEBO; TRIACYLGLYCEROL; URATE;

ADULT; AGED; ARTICLE; BODY WEIGHT; BONE DENSITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRACTURE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84964240560     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12428     Document Type: Article

References (37)

1. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36.
2. Centers for Disease Control and Prevention. National diabetes fact sheet. 2011. Available from URL: http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed 7 February 2012.
3. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77-82.
4. Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschope D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 2012; 11: 122.
5. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
6. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl. 1): S14-80.
7. Sinclair A, Morley JE, Rodriguez-Manas L et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012; 13: 497-502.
8. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
9. Stenlöf K, Cefalu WT, Kim K-A et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
10. Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515.
11. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
12. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84.
13. Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
14. Lavalle-González F, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592.
15. Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
16. Forst T, Guthrie R, Goldenberg R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477.
17. Sinclair A, Bode B, Harris S et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014; 14: 37.
18. Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545.
19. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672.
20. Polidori D, Sha S, Ghosh A, Plum-Morschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: E867-871.
21. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results. Postgrad Med 2014; 126: 16-34.
22. Viberti G, Kahn SE, Greene DA et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-1743.
23. Manini TM. Energy expenditure and aging. Ageing Res Rev 2010; 9: 1-11.
24. Leiter LA, Yoon K-H, Arias P et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care 2014; DOI: 10.2337/dc13-2762.
25. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
26. Hach T, Gerich JE, Salsali A, Kim G, Hantal S, Woerle HJ etal. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials (Abstract 69-LB). Diabetes 2013; 62(Suppl. 1): LB19.
27. Neal B, Perkovic V, de Zeeuw D et al. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013; 166: 217-223.
28. Food and Drug Administration. FDA Briefing Document. NDA 204042. Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals, Inc. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Silver Spring, MD. 10 January 2013.
29. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over two years. Diabetes Obes Metab 2014; 16: 124-136.
30. Ridderstrale M, Andersen KR, Zeller C et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700.
31. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576.
32. Nyirjesy P, Sobel JD, Fung A etal. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109-1119.
33. Ji L, Han P, Liu Y, Yang G, Dieu Van NK, Vijapurkar U etal. Canagliflozin in Asian subjects with type 2 diabetes on metformin (MET) alone or in combination with sulphonylurea (SU). Diabetes Obes Metab 2015; 17: 23-31.
34. Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013; 15: 1136-1145.
35. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745.
36. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
37. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.